Furthermore, studies conducted by Kuo et al. [85], Nguyen et al. [86], and Tada et al. [87] showed that a high pre-treatment serum ALB–BIL grade independently predicted worse OS in HCC patients receiving molecular targeted therapy with sorafenib. Here, ALB is linked to hepatocellular carcinoma.